May 14th 2024
During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
BCMA-Directed Therapies Taking Hold in Multiple Myeloma
November 7th 2019There are at least two dozen different B-cell maturation antigen-directed therapies being explored in clinical trials, Sham Mailankody, MBBS, told attendees at the 37 Annual CFS. Mailankody, an assistant attending physician at Memorial Sloan Kettering Cancer Center in New York, New York, highlighted the most promising anti-BCMA agents across several modalities, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.
Read More
Treatment of Smoldering Myeloma Delays Disease Progression, Yet Questions Remain
November 6th 2019There are many greatdebates in the field of multiple myeloma, and one that is becoming increasingly relevant in the era of modern therapies is whether or not to treat patients with asymptomatic disease. While the etiology of MM remains unknown, a major advancement in understanding myeloma pathogenesis has been the observation that all patientsprogress, albeit at differing rates, through an asymptomatic phase of either monoclonal gammopathy of undetermined significance or smoldering MM.
Read More
Expert Predicts Immunotherapy Combos Will Transform Treatment in Multiple Myeloma
October 8th 2019<br /> In the future, we’re going to do combination therapies. They will be used in a subset of patients better defined by profiling,” Kenneth C. Anderson, MD, told an audience at the Charlotte Plasma Cell Disorder Congress in North Carolina.
Read More
New Myeloma Induction Leads to Better Survival
October 7th 2019Successful induction regimens can reduce the burden of disease and prolong the durability of treatment response, time to disease progression, and overall survival for patients with newly diagnosed multiple myeloma, all while minimizing toxicity, according to Saad Usmani, MD, chief of the Plasma Cell Disorders Program and director of clinical research in hematologic malignancies at Levine Cancer Institute of the Carolinas Medical Center in Charlotte, North Carolina.
Read More
A Look Back at FDA News from September 2019
October 1st 2019In September 2019, the FDA approved new treatment options for patients with endometrial carcinoma, prostate cancer, and multiple myeloma. The FDA also expanded the indication for the Cologuard noninvasive screening test for colorectal cancer. During the month there were 2 breakthrough therapy designations, 2 fast track designations, 1 orphan drug designation, and 1 priority review granted.
Read More
FDA Approves Daratumumab + VTD Combo for Frontline Multiple Myeloma
September 26th 2019The combination of daratumumab plus bortezomib, thalidomide, and dexamethasone (VTD) has been approved by the FDA for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant.
Read More
STOMP Trial Shows High Activity in R/R Multiple Myeloma With Selinexor Regimen
September 17th 2019Selinexor plus lenalidomide and dexamethasone, an all-oral triplet, was found to be highly active in patients with relapsed or refractory multiple myeloma, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop. The regimen is also well tolerated and especially active in patients who did not receive lenalidomide prior to the trial.
Read More
Carfilzomib Triplet Improves PFS in Phase III Myeloma Trial
September 17th 2019The combination of carfilzomib, dexamethasone, and daratumumab led to a 37% reduction in the risk of progression or death compared with carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma in the phase III CANDOR trial. According to a press release from Amgen, this met the primary endpoint of progression-free survival for the trial.
Read More
The combination of melflufen and dexamethasone showed antitumor activity in patients with relapsed or refractory multiple myeloma, both in those with and those without extramedullary disease, according to data from the phase II HORIZON study presented at the 17th International Myeloma Workshop.
Read More
Daratumumab Plus VRd Improved Depth of Response in Transplant-Eligible, Newly Diagnosed Myeloma
September 15th 2019The GRIFFIN study showed that the addition of daratumumab to bortezomib, lenalidomide, and dexamethasone, improved stringent complete response in transplant-eligible patients with newly diagnosed multiple myeloma without affecting stem cell mobilization or hematopoietic reconstitution, according to results presented at the 17th International Myeloma Workshop.
Read More
Antitumor Activity Observed With Iberdomide in Heavily Pretreated Myeloma
September 15th 2019Novel agent iberdomide in combination with dexamethasone was safe and demonstrated antitumor activity in patients with relapsed/refractory multiple myeloma who were heavily pretreated, according to findings from a phase Ib/IIa trial presented at the 17th International Myeloma Workshop.
Read More
Promising PFS Shown With Isatuximab Triplet in High-Risk Multiple Myeloma
September 15th 2019In an interview with <em>Targeted Oncology</em> during the 17th IMW Scientific Program, Simon J. Harrison, MBBS, PhD, discussed the subgroup findings from the ICARIA-MM study in relapsed/refractory multiple myeloma.
Read More
Melflufen Plus Dexamethasone Safe and Effective For R/R Multiple Myeloma
September 15th 2019Paul G. Richardson, MD, clinical program leader and director of clinical research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and RJ Corman Professor of Medicine, Harvard School of Medicine, discusses the interesting safety and efficacy profiles of the HORIZON trial.
Watch
Efficacy Seen With Isatuximab Regimen in High-Risk Multiple Myeloma
September 14th 2019The addition of isatuximab to carfilzomib, lenalidomide, and dexamethasone led to a response rate in all 10 patients included in a safety run-in cohort of the phase II, multicenter GMMG-CONCEPT trial.
Read More
Daratumumab-Based Quadruplet Demonstrates Efficacy in High-Risk Myeloma Subgroups
September 14th 2019Daratumumab in combination with bortezomib, thalidomide, and dexamethasone demonstrated benefit compared with VTd alone in subgroup analyses of patients with high-risk multiple myeloma from the phase III CASSIOPEIA trial.
Read More
Chari Considers Choosing Proteasome Inhibitors in Relapsed Multiple Myeloma
August 29th 2019During a Targeted Oncology case-based peer perspectives presentation, Ajai Chari, MD, discussed with a group of physicians the treatment options available to patients with relapsed multiple myeloma. Chari explained the various treatment options and the supporting data based around a case scenario of a patient with multiple myeloma who relapses.
Read More
Early Data From DREAMM-2 Trial Promising for Belantamab Mafodotin in Relapsed Multiple Myeloma
August 23rd 2019Belantamab mafodotin, an investigational antibody–drug conjugate, demonstrated a clinically meaningful overall response rate among patients with relapsed multiple myeloma in early results from the DREAMM-2 trial, according to a press release from GlaxoSmithKline. This met the primary endpoint of the pivotal phase II trial.
Read More
Selinexor Induces Meaningful Survival in Heavily Pretreated Multiple Myeloma in STORM Trial
August 22nd 2019Selinexor plus dexamethasone induced objective responses and a significant overall survival among heavily pretreated patients with multiple myeloma, according to results from the phase IIb STORM trial published in <em>The New England Journal of Medicine.</em>
Read More
Approved Combinations and Novel Agents Expand Therapy Options Across Multiple Myeloma Settings
August 19th 2019The addition of novel agents and combinations to the treatment of multiple myeloma, along with improvements in personalized therapy based on genetic profiles of individual patients, are propelling care forward with their potential for prolonging survival and deepening responses beyond those from the current standards of care.<br />
Read More
Small Molecules Making a Resurgence in the Treatment of Multiple Myeloma
August 15th 2019In an interview with <em>Targeted Oncology </em>following a presentation at the Charlotte Plasma Cell Disorder Congress, Cesar Rodriguez Valdes, MD explained how small molecules fit into the myeloma treatment and notes the ongoing research that shows promise for the next class of small molecules in the future.<br />
Read More
Pomalidomide-Based Triplets Improve Responses in Relapsed/Refractory Multiple Myeloma
August 14th 2019Peter Voorhees, MD, discusses the latest data for the use of pomalidomide-containing regimens for the treatment of patients with relapsed/refractory multiple myeloma. He highlights data from 2 randomized clinical trials that demonstrated an improvement in responses with pomalidomide-based triplets.
Watch
Selinexor Approval Shows Promising Future for R/R Multiple Myeloma Treatment
August 9th 2019In an interview with <em>Targeted Oncology</em>, Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, talked through the current options for the treatment of patients with relapsed/refractory multiple myeloma and the clinical trial data that will shape the future of the field.
Read More
Responses Improved for Newly Diagnosed Myeloma in Phase III CASSIOPEIA Trial
July 11th 2019Phillipe Moreau, MD, discusses the results from the randomized, open-label, multicenter phase III CASSIOPEIA trial. The results of the trial led to a priority review designation from the FDA for the combination of daratumumab plus bortezomib, thalidomide, and dexamethasone for patients with treatment-naïve multiple myeloma who are candidates for autologous stem cell transplant.
Watch
FDA Reviewing Isatuximab BLA in Relapsed/Refractory Multiple Myeloma
July 10th 2019The FDA has accepted and is reviewing a Biologics License Application (BLA) for isatuximab as a potential treatment for patients with relapsed or refractory multiple myeloma. A target action date of April 30, 2020 has been set by the agency.<sup>1</sup><br />
Read More
Frontline 4-Drug Regimen Leads to Promising Responses in Transplant-Eligible Multiple Myeloma
July 10th 2019The 4-drug regimen of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone induced a high percentage of stringent complete responses compared with VRd alone in patients with newly diagnosed multiple myeloma who are eligible for high-dose chemotherapy and an autologous stem cell transplantation, according to topline results of the GRIFFIN trial. This met the primary endpoint of the phase II trial.
Read More